Sangamo Biosciences is putting a different spin on gene therapy.
Infographic: Messing with HIV
View full size JPG | PDFLUCY READING-IKKANDA
Sangamo Biosciences is putting a different spin on gene therapy. Rather than replace or supplement a mutated gene with an accurate copy, Sangamo researchers are introducing a mutant copy of the gene for the HIV co-receptor CCR5 into the T cells of HIV patients. This prevents the expression of CCR5 on the cell’s surface, and thus inhibits HIV from infecting cells.
Add The Scientist as a preferred Google source to see more of our trusted coverage.
Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.
View Full Profile
Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.
View this Issue
Explore how blood-based biomarkers perform across Alzheimer’s disease stages, including AIBL Study findings comparing p-Tau217 and other markers against amyloid-beta and tau PET reference standards.
Learn how microvolume UV/Vis and DLS can accelerate, automate, and streamline protein developability screening while reducing sample requirements.
Assess protein sample purity and homogeneity in minutes with mass photometry using only nanograms of sample.
Explore how super-resolution microscopy enables particle-level characterization of lipid nanoparticle composition, cargo loading, heterogeneity, and stability, providing complementary insights for formulation development and optimization.
The placements follow the commercial launch of Pyxa at the Advances in Genome Biology and Technology (AGBT) meeting in February 2026 and mark the company's transition from Early Access into global commercial availability.
The CellRaft AIR streamlines antibody discovery with imaging, functional screening, and gentle isolation of viable single B cells and hybridomas, helping verify monoclonality and identify high producing clones faster.
Load plasma directly into prefilled cartridges, no pretreatment, no ethanol. Under 30 minutes of instrument run time, up to 48 samples in parallel, with a high-throughput format also available.
Two Paige tools, powered by the Virchow pathology foundation model, are now available within a single image management workspace for oncology research.
